Workup for Newly Discovered Hypertension in a 56-Year-Old Female
For a 56-year-old woman with newly discovered hypertension, obtain a basic metabolic panel, lipid profile, urinalysis with albumin-to-creatinine ratio, ECG, and calculate 10-year cardiovascular risk using PREVENT equations to guide treatment decisions.
Initial Diagnostic Workup
The 2025 AHA/ACC guidelines 1 and 2024 ESC guidelines 2 provide a clear framework for evaluating newly diagnosed hypertension. The workup serves four critical purposes: confirming sustained hypertension, identifying cardiovascular risk factors, detecting target organ damage, and screening for secondary causes when indicated.
Essential Laboratory Tests
Order these tests within the first evaluation:
- Basic or comprehensive metabolic panel (BMP/CMP) - assesses kidney function (creatinine, eGFR), electrolytes (particularly potassium for aldosterone screening), and glucose
- Lipid profile - identifies dyslipidemia as an additional cardiovascular risk factor
- Urinalysis with albumin-to-creatinine ratio - detects early kidney damage and proteinuria 1
- Fasting glucose or HbA1c - screens for diabetes
- Complete blood count (CBC) - baseline assessment
- Thyroid-stimulating hormone (TSH) - rules out thyroid dysfunction as secondary cause
- Electrocardiogram (ECG) - identifies left ventricular hypertrophy or other cardiac abnormalities 1, 2
Critical Clinical Assessment
During history and physical examination, specifically evaluate:
- Blood pressure confirmation: Verify elevated readings with proper technique; consider home blood pressure monitoring or ambulatory monitoring to confirm diagnosis 1
- Cardiovascular risk factors: smoking, family history of premature cardiovascular disease, physical inactivity, dietary patterns
- Symptoms suggesting secondary causes: muscle weakness, palpitations, headaches, sweating episodes (pheochromocytoma), snoring/daytime sleepiness (sleep apnea)
- Medication review: NSAIDs, decongestants, oral contraceptives, steroids that may elevate blood pressure
- Target organ damage signs: fundoscopic changes, carotid bruits, cardiac murmurs, peripheral pulses, neurological deficits
Risk Stratification and Treatment Planning
Calculate 10-year cardiovascular risk using PREVENT equations (replacing the older race-based calculators) 1. This is crucial because:
- If PREVENT risk ≥7.5%: Initiate antihypertensive medication immediately if BP ≥130/80 mmHg
- If PREVENT risk <7.5%: Trial lifestyle modifications for 3-6 months; start medication if BP remains ≥130/80 mmHg 1
At age 56, this patient likely falls into a category where medication decisions depend heavily on her calculated cardiovascular risk and presence of comorbidities (diabetes, chronic kidney disease, prior cardiovascular disease).
Secondary Hypertension Screening
Consider expanded screening for primary aldosteronism if:
- Hypertension is resistant to treatment
- Spontaneous or diuretic-induced hypokalemia is present
- Adrenal incidentaloma is found
- Early-onset hypertension or family history of early stroke 1, 3
The 2025 guidelines 1 have broadened screening recommendations for primary aldosteronism, as it's more common than previously recognized and carries excess cardiorenal risk. Obtain aldosterone-to-renin ratio in appropriate candidates, using medication-tolerant interpretation 3.
Common Pitfalls to Avoid
Do not rely on single office readings - white coat hypertension is common in middle-aged women. Home blood pressure monitoring provides more accurate assessment 1.
Do not skip the urinalysis with albumin-to-creatinine ratio - this is now emphasized as routine testing 1 but remains underutilized in practice, with only 21.9% completion rates in real-world data 4.
Do not delay treatment while pursuing extensive secondary cause workup - unless clinical features strongly suggest secondary hypertension, most patients have primary hypertension and benefit from prompt treatment initiation 5, 6.
Evidence Quality Note
Despite clear guideline recommendations 1, 2, real-world adherence to recommended testing is alarmingly low, with completion rates ranging from 9.6% (fasting glucose) to 42.7% (BMP/CMP) 4. Female patients show lower completion rates for several tests compared to males 4, highlighting a care gap that must be addressed in this demographic.
The 2025 AHA/ACC guideline 1 represents the most current evidence-based approach, maintaining the <130/80 mmHg treatment goal established in 2017 while refining risk assessment tools and emphasizing team-based care and home monitoring.